Caris Life Sciences Financial Statements
NASDAQ: CAIHealth CareMedical SpecialitiesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Caris Life Sciences revenue and earnings
In fiscal 2025, Caris Life Sciences generated $812.0 million in revenue, up 97.0% from fiscal 2024, its 2nd consecutive year of revenue growth. Caris Life Sciences reported a net loss of $68.1 million, compared with a loss of $281.9 million a year earlier. Operating margin was 5.6%.
Diluted earnings per share came in at -$3.22. Over the last 2 fiscal years, CAI's revenue has grown at a 62.9% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Caris Life Sciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 |
|---|---|---|---|
| Revenue | 812.03M | 412.26M | 306.13M |
| Revenue growth (YoY) | +96.97% | +34.67% | — |
| Research & Development | 101.58M | 113.92M | 116.88M |
| Selling, General & Admin | 392.47M | 321.99M | 291.98M |
| Operating Income | 45.11M | -257.12M | -319.55M |
| Interest Expense | 56.85M | 50.02M | 31.61M |
| Other Income (Expense) | -113.20M | -24.77M | -21.86M |
| Pretax Income | -68.09M | -281.89M | -341.42M |
| Income Tax | 0 | 0 | 0 |
| Net Income | -68.09M | -281.89M | -341.42M |
| Net Income growth (YoY) | — | — | — |
| EPS (Basic) | -3.22 | -10.66 | -13.24 |
| EPS (Diluted) | -3.22 | -10.66 | -13.24 |
| Shares Outstanding (Basic) | 167.21M | 35.50M | 34.94M |
| Shares Outstanding (Diluted) | 167.21M | 35.50M | 34.94M |
| EBITDA | 67.73M | -208.21M | -270.55M |
| Operating Margin | 5.56% | -62.37% | -104.38% |
| Net Margin | -8.38% | -68.38% | -111.53% |
This table shows 3 annual periods of Caris Life Sciences's income statement, from FY 2025 back to FY 2023, across 16 line items including revenue, research & development, selling, general & admin. Values in USD; B = billions, M = millions. Fiscal periods follow CAI's reporting calendar. What is a income statement?